Complete analysis of pitobrutinib/pitubrutinib compound patents, a must-read for scientific research parties!

Pirtobrutinib is a new, non-covalent, reversible Bruton's tyrosine kinase (BTK) inhibitor that is mainly used to treat a variety of B-cell malignancies, especially in patients with resistance or intolerance to previous generation BTK inhibitors (such as ibrutinib and acalabrutinib). It has shown good efficacy. Currently, Pitobrutinib has been approved by the FDA for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two therapies in the past, and its potential indications in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and other diseases are actively studied in clinical trials. Its biggest advantage is that it can maintain effective binding and inhibitory activity even if the BTK gene has the C481 mutation, so it is particularly suitable for cases where previous BTK inhibitors have failed.

The recommended dose of this drug is usually 200 mg once daily, taken orally, regardless of food. Because its mechanism of action is reversible binding and does not form a covalent bond like ibrutinib, pitobrutinib is easier to control pharmacokinetically and has a shorter half-life, making it more flexible in drug management and dose adjustment. For patients who need to suspend treatment due to adverse reactions, drug interactions or other reasons, the treatment method is relatively simple. Severe adverse events or disease progression may require permanent discontinuation and evaluation of alternatives.

Clinical data show that pitobrutinib has a significant response rate in a variety of refractory B-cell tumors and has a good safety profile. Common side effects include fatigue, diarrhea, ecchymosis, upper respiratory tract infection, neutropenia, etc. Most of them are controllable adverse reactions. When discontinuing medication, it is not recommended that patients discontinue it on their own. They should make gradual adjustments under the guidance of a professional physician to avoid a rebound in the condition or aggravation of side effects due to sudden discontinuation of medication.

Reference materials:https://go.drugbank.com/drugs/DB17472